These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23373898)

  • 1. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation.
    McNamara KM; Yoda T; Miki Y; Chanplakorn N; Wongwaisayawan S; Incharoen P; Kongdan Y; Wang L; Takagi K; Mayu T; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Ohuchi N; Sasano H
    Cancer Sci; 2013 May; 104(5):639-46. PubMed ID: 23373898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer.
    Shibahara Y; Miki Y; Sakurada C; Uchida K; Hata S; McNamara K; Yoda T; Takagi K; Nakamura Y; Suzuki T; Ishida T; Ohuchi N; Sasano H
    Hum Pathol; 2013 Oct; 44(10):2338-45. PubMed ID: 23953348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
    McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological Relevance and Prognostic Value of Androgen Receptor in Mammary Paget's Disease with Underlying Invasive Ductal Carcinoma.
    Zhang M; Meng X; Guo C; Liu J; Xing Z; Wang X; Wang X
    Oncol Res Treat; 2020; 43(7-8):346-353. PubMed ID: 32645702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
    Suzuki T; Darnel AD; Akahira JI; Ariga N; Ogawa S; Kaneko C; Takeyama J; Moriya T; Sasano H
    J Clin Endocrinol Metab; 2001 May; 86(5):2250-7. PubMed ID: 11344235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.
    Yoda T; McNamara KM; Miki Y; Takagi M; Rai Y; Ohi Y; Sagara Y; Tamaki K; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H
    Cancer Sci; 2014 Nov; 105(11):1503-9. PubMed ID: 25230018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Wang L; Chan MS; Wing L; Yiu CC; Chow LW; Sasano H
    Horm Cancer; 2011 Feb; 2(1):73-81. PubMed ID: 21761341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D; Xu S; Zhang Q; Zhao W
    Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer.
    McNamara KM; Yoda T; Miki Y; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Nishimura R; Arima N; Tamaki K; Ishida T; Ohuchi N; Sasano H
    Int J Biol Markers; 2015 May; 30(2):e184-9. PubMed ID: 25588857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.
    Kikuchi K; McNamara KM; Miki Y; Moon JY; Choi MH; Omata F; Sakurai M; Onodera Y; Rai Y; Ohi Y; Sagara Y; Miyashita M; Ishida T; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2017 Dec; 166(3):709-723. PubMed ID: 28831645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
    McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
    Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
    Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
    Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
    PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer.
    Zhao H; Yang M; Zhao J; Wang J; Zhang Y; Zhang Q
    Med Oncol; 2013 Mar; 30(1):475. PubMed ID: 23371253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of AR, 5αR1 and 5αR2 in bladder urothelial carcinoma and relationship to clinicopathological factors.
    Hata S; Ise K; Azmahani A; Konosu-Fukaya S; McNamara KM; Fujishima F; Shimada K; Mitsuzuka K; Arai Y; Sasano H; Nakamura Y
    Life Sci; 2017 Dec; 190():15-20. PubMed ID: 28947209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
    Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
    Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between androgen receptor status and prognosis in triple negative breast cancer.
    Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
    J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.